Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus chemotherapy in recurrent/metastatic TNBC
NCT06367088Phase 2Recruiting
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in triple-negative breast cancer (TNBC). Started May 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06367088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06367088.